DLC1 and liver cancer: This latter result is like what has been previously reported for the impact of inhibitory RNA knockdown of endogenous EZH2 on endogenous DLC1 mRNA in liver cancer cell lines37; the DZNep inhibitor used in that report is a pan-histone methylase inhibitor38, which precludes an EZH2-specific interpretation of results obtained with it.